Hasco-lek

What Hasco-lek does

Hasco-Lek S.A. is a Polish pharmaceutical manufacturer headquartered in Wrocław, Poland, operating since the late 1980s as part of the broader Hasco Group. The company produces a portfolio of generic and innovative pharmaceutical products in capsule, tablet, suppository, and gel dosage forms, including the orodispersible analgesic Mel, the heparin-based Fortiven Activ Gel, the antiviral Hascovir, and a family of liposomal-technology products (Lipożel, Ferovit, Magmil). Manufacturing is conducted on GMP-certified production lines and supported by the Novasome Research and Development Centre, which holds both R&D Centre status (granted 2014) and scientific institute status (confirmed 2018), and is equipped with advanced analytical instrumentation including GC-MS, LC-MS, confocal Raman microscopy, XRPD, TGA-DSC, and BET.

The company operates a vertically integrated business model that owns R&D (Novasome), manufacturing (PPF Hasco-Lek), and wholesale distribution (PCF Procefar) within the Hasco Group structure. Domestic revenues flow primarily through sales to Polish pharmacies, pharmacy chains, and hospital procurement, distributed via PCF Procefar's wholesale network and a recently inaugurated (~80 million PLN investment) automated distribution-logistics center near Łódź/Stryków featuring Poland's first A-Frame with PUMA robotic order-picking technology. A dedicated export department manages sales to over 40 international markets.

Hasco-Lek is publicly listed on the Warsaw Stock Exchange with fully paid share capital of PLN 329,944,036 and operates with 1,001–5,000 employees. Governance includes the Han family in senior leadership (Agnieszka Han and Tomasz Han as Vice Presidents), and the company actively engages in pharmaceutical-industry policy discourse through senior leadership participation in the European Economic Congress and Health Challenges Congress.

Name

Hasco-lek

Legal name

Przedsiębiorstwo Produkcji Farmaceutycznej HASCO-LEK S.A.

Website

https://hasco-lek.pl

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Hasco-Lek S.A. is a Polish pharmaceutical manufacturer producing generic and innovative medicines across multiple dosage forms. The vertically integrated Hasco Group company owns R&D, manufacturing, and wholesale distribution, serving Polish pharmacies and exporting to over 40 international markets.

Ownership category

akta.pro rank

Headquarters

HQ city

Wroclaw

HQ country

Poland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical product sales (domestic): Sale of generic and innovative pharmaceutical products (capsules, tablets, suppositories, gels) to pharmacies and hospital procurement channels in Poland through PCF Procefar wholesale operations.
2. International exports: Export sales of pharmaceutical products to over 40 international markets, managed through the business development department.
3. Wholesale distribution services: PCF Procefar serves as the pharmaceutical wholesale company for the Hasco Group, distributing products to pharmacies and other wholesale customers throughout Poland.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Hasco-Lek is a Polish pharmaceutical manufacturer producing generic and innovative medicines in capsule, tablet, suppository, and gel dosage forms, sold under brand names including Mel (orodispersible analgesic), Fortiven Activ Gel (heparin-based topical), Hascovir (antiviral), Lipożel, Ferovit, and Magmil (liposomal products). Products are manufactured on GMP-certified production lines and distributed domestically through the wholesale arm PCF Procefar to Polish pharmacies and hospitals, with parallel export to more than 40 international markets.

Product overview

Hasco-Lek S.A. is a Polish pharmaceutical manufacturer established in the 1980s, operating as part of the HASCO Group. The company produces a comprehensive portfolio of pharmaceutical products including Mel (orodispersible analgesic), Fortiven Activ Gel (heparin-based product), Hascovir (antiviral), and several products utilizing proprietary liposomal technology including Lipożel, Ferovit, and Magmil. Production capabilities include modern capsule, tablet, and suppository manufacturing lines compliant with GMP standards. The portfolio is supported by the Novasome Research and Development Centre, established in 2004, which conducts research across medicine, pharmacy, chemistry, and cosmetics sectors, and holds both Research and Development Centre status and scientific institute status.

Differentiator

Problem solved

Functional benefit

Products and services

• Mel Orodispersible analgesic pharmaceutical product manufactured by Hasco-Lek for pain relief, sold to pharmacies and wholesalers as part of the company's branded portfolio.
• Fortiven Activ Gel Topical pharmaceutical gel containing a high dose of heparin for anti-inflammatory/topical application, manufactured and distributed by Hasco-Lek through pharmacies and wholesalers.
• Hascovir Antiviral pharmaceutical product utilizing Hasco-Lek's patented liposomal drug delivery technology to improve bioavailability and reduce side effects.
• Lipożel Pharmaceutical product utilizing Hasco-Lek's patented liposomal technology to enclose active substances in a double-layer lipid shell, improving bioavailability.
• Ferovit Pharmaceutical/dietary supplement utilizing Hasco-Lek's patented liposomal technology for improved delivery of active substances.
• Magmil Pharmaceutical/dietary supplement utilizing Hasco-Lek's patented liposomal technology for enhanced mineral absorption.

Quantifiable outcome

• Over 40 international markets served with pharmaceutical products
• +1 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered minor and core.

• BRIDGE FoundationminorGTM or Marketing Partner · 1 April 2026BRIDGE Foundation organized the East x West Forum conference held in Wrocław on April 9, 2026. Hasco-Lek served as a partner of the event, with Agnieszka Han (Vice President) participating in the 'Polska 28-milionowa?' debate. The forum gathered business, government, and expert representatives to discuss challenges for Poland and Central-Eastern Europe.
• ASTORcoreTechnology or Integration · 1 January 2025ASTOR was responsible for designing and implementing the automated pharmacy order picking system (A-Frame with PUMA technology) at the new PCF Procefar distribution center near Łódź (Stryków). This represents the first such installation in Poland, enabling high-speed automated order processing of up to 5 packages per second.
• Harden ConstructioncoreImplementation/ SI/ Consulting Partner · 1 January 2025Harden Construction served as the general contractor for the 8,300 m² specialized pharmaceutical distribution center near Łódź (Stryków). The facility meets the highest pharmaceutical industry standards including GDP (Good Distribution Practice) requirements. Construction completed in 2025-2026. This was Harden Construction's eighth investment in the Łódź region and second in the Stryków municipality.
• PCF Procefar (Hasco Group)coreStrategic or Co-development Partner · 1 January 2025PCF Procefar is the Hasco Group's pharmaceutical wholesale company responsible for distributing all Hasco-Lek products to pharmacies and wholesale customers across Poland. It served as the investor for the 80 million PLN distribution center near Łódź. Managed by Maciej Podraza (Board Member of Hasco-Lek and CEO of PCF Procefar) and Maciej Wolski (Operations Director).
• Novasome Research and Development Centre (part of Hasco Group)coreStrategic or Co-development Partner · 1 January 2004Novasome was established in 2004 as part of the Hasco Group to conduct research and development as well as expert and analytical activities in medicine, pharmacy, chemistry, and cosmetics. Managed by Tomasz Han (Vice President) since 2012. Holds Research and Development Centre status (granted 2014) and scientific institute status (confirmed 2018). GMP certified for manufacturing and quality control.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Emerging players

• Lupin Pharmaceuticals: Indian-headquartered generic pharmaceutical company with growing European presence and complex generics/liposomal technology focus. Relevant emerging peer given overlapping interest in liposomal delivery and European generics market entry strategies that compete with Hasco-Lek's export business.
• Vitamed (PHU Vitamed): Polish pharmaceutical company focused on dietary supplements and OTC products with proprietary formulations. Comparable to Hasco-Lek on the supplement/dietary side (Ferovit, Magmil), but smaller and more focused on consumer health channels rather than prescription pharma.

Direct peers

• Gedeon Richter: Hungarian-headquartered Central European pharmaceutical manufacturer with a strong generics portfolio and expanding specialty/OTC segments. Comparable to Hasco-Lek in regional European positioning, multi-therapeutic area generics focus, and emerging markets export strategy.
• Polpharma: Polpharma is Poland's largest pharmaceutical manufacturer, producing generic and OTC medicines with vertically integrated manufacturing and distribution. It is the most direct comparable to Hasco-Lek given overlapping Polish market presence, generic portfolio focus, and integrated supply chain.
• KRKA: Slovenian pharmaceutical company focused on generic prescription drugs, OTC products, and animal health with strong presence across Central and Eastern Europe, CIS, and Western Europe. Highly comparable to Hasco-Lek in product mix (generics + proprietary formulations), geographic coverage, and export-led growth model.
• Zentiva: European generics and consumer healthcare company headquartered in Prague with broad portfolio across multiple dosage forms. Direct peer to Hasco-Lek given similar Central European base, generics focus, integrated R&D-manufacturing-distribution model, and pan-European market reach.

Regional players

• Polfa Tarchomin: Polish state-owned pharmaceutical manufacturer producing generic and specialty drugs with focus on domestic Polish market. Comparable to Hasco-Lek as a Polish pharma peer with similar regulatory positioning, though its ownership structure and product mix differ.

Broad incumbents

• Teva Pharmaceutical Industries: Global leader in generic pharmaceuticals with extensive European operations including significant Central European presence. Comparable to Hasco-Lek in generic pharmaceutical focus, but operates at much larger scale with biosimilars and specialty franchises beyond Hasco-Lek's current scope.
• Stada Arzneimittel: Major European generics and consumer healthcare company with broad portfolio across generics, specialty, and consumer health. Comparable to Hasco-Lek in product categories and European market focus, but significantly larger scale and broader geographic footprint make it a broad incumbent rather than direct peer.

Others

• Sandoz Group: Recently spun-off Novartis generics division focused on generic pharmaceuticals and biosimilars with strong European footprint. Comparable to Hasco-Lek in product categories (generic oral solid doses, topicals), but operates at global scale with substantially larger manufacturing capacity and R&D investment.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/c/hascolek
• Facebookfacebook.com/GrupaHasco
• LinkedInpl.linkedin.com/company/hasco-lek-s.a.

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hasco-lek